Abstract

Cognitive decline (CD) is a major symptom of mild cognitive impairment (MCI). Patients with MCI have an increased likelihood of developing Alzheimer's disease (AD). Although a cure for AD is currently lacking, medication therapies and/or daily training in the early stage can alleviate disease progression and improve patients' quality of life. Accordingly, investigating CD-related biomarkers via brain imaging devices is crucial for early diagnosis. In particular, "portable" brain imaging devices enable frequent diagnostic checks as a routine clinical tool, and therefore increase the possibility of early AD diagnosis. This study aimed to comprehensively investigate functional connectivity (FC) in the prefrontal cortex measured by a portable functional near-infrared spectroscopy (fNIRS) device during a working memory (WM) task known as the delayed matching to sample (DMTS) task. Differences in prefrontal FC between healthy control (HC) (n = 23) and CD groups (n = 23) were examined. Intra-group analysis (one-sample t-test) revealed significantly greater prefrontal FC, especially left- and inter-hemispheric FC, in the CD group than in the HC. These observations could be due to a compensatory mechanism of the prefrontal cortex caused by hippocampal degeneration. Inter-group analysis (unpaired two-sample t-test) revealed significant intergroup differences in left- and inter-hemispheric FC. These attributes may serve as a novel biomarker for early detection of MCI. In addition, our findings imply that portable fNIRS devices covering the prefrontal cortex may be useful for early diagnosis of MCI.

Highlights

  • Alzheimer’s disease (AD) is a chronic progressive neurodegenerative brain disease that typically presents as subtle failures in memory that gradually becomes more acute [1]

  • Our results indicate that prefrontal functional connectivity (FC), measured with the functional near-infrared spectroscopy (fNIRS) device while performing a delayed matching to sample (DMTS) task, has distinct characteristics between healthy control (HC) and Cognitive decline (CD) groups

  • We measured and analyzed prefrontal FC of HC and CD groups using a portable fNIRS during a working memory (WM) task

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a chronic progressive neurodegenerative brain disease that typically presents as subtle failures in memory that gradually becomes more acute [1]. A cure for AD is currently lacking, medication therapies and/or daily training in the early stage can alleviate disease progression and improve patients’ quality of life [3,4]. Early diagnosis of AD is of substantial clinical importance as these therapeutic strategies are more effective during the earlier stages of AD. Mild cognitive impairment (MCI) is considered to be an intermediate state of cognitive impairment between normal aging and AD [5,6,7]. They do not meet the clinical criteria for AD [8], patients with MCI are more likely to develop AD [9]. Researchers have focused on the major symptoms of MCI

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call